Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhuoxin Sun

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Acta Haematologica|July 24, 2019
Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)Sanford Kempin, Zhuoxin Sun, Neil E Kay, et al.
The Oncologist|February 17, 2021
A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 StudyJohn M Varlotto, Zhuoxin Sun, Bonnie Ky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2007
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trialHenning Mouridsen, Aparna Keshaviah, Alan S Coates, et al.
The New England Journal of Medicine|September 25, 2009
Anthracycline dose intensification in acute myeloid leukemiaHugo F Fernandez, Zhuoxin Sun, Xiaopan Yao, et al.
Breast Cancer Research : BCR|November 7, 2012
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXAlan S Coates, Ewan K A Millar, Sandra A O'Toole, et al.
Nature Neuroscience|January 18, 2006
Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease modelsMichelle Day, Zhongfeng Wang, Jun Ding, et al.
Breast Cancer Research and Treatment|February 4, 2014
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequencesAndrea Decensi, Zhuoxin Sun, Aliana Guerrieri-Gonzaga, et al.
British Journal of Haematology|November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup studyThomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Breast Cancer Research and Treatment|November 7, 2020
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trialManuela Rabaglio, Zhuoxin Sun, Rudolf Maibach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Acta Haematologica|July 24, 2019
Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)Sanford Kempin, Zhuoxin Sun, Neil E Kay, et al.
The Oncologist|February 17, 2021
A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 StudyJohn M Varlotto, Zhuoxin Sun, Bonnie Ky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2007
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trialHenning Mouridsen, Aparna Keshaviah, Alan S Coates, et al.
The New England Journal of Medicine|September 25, 2009
Anthracycline dose intensification in acute myeloid leukemiaHugo F Fernandez, Zhuoxin Sun, Xiaopan Yao, et al.
Breast Cancer Research : BCR|November 7, 2012
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXAlan S Coates, Ewan K A Millar, Sandra A O'Toole, et al.
Nature Neuroscience|January 18, 2006
Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease modelsMichelle Day, Zhongfeng Wang, Jun Ding, et al.
Breast Cancer Research and Treatment|February 4, 2014
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequencesAndrea Decensi, Zhuoxin Sun, Aliana Guerrieri-Gonzaga, et al.
British Journal of Haematology|November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup studyThomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Breast Cancer Research and Treatment|November 7, 2020
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trialManuela Rabaglio, Zhuoxin Sun, Rudolf Maibach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Pageof 8